

## **How to enrol 2<sup>nd</sup> and subsequent line lung cancer patients onto MoST substudies**

Treatment-refractory metastatic lung cancer patients are potentially eligible to enrol on the pan-cancer stream of MoST substudies, regardless of whether they were previously screened through ASPIRATION.

This includes all MoST substudies currently open to pan-cancer, including:

- MoST 12: BRAF V600 (vemurafenib + cobimetinib)
- MoST 13: ROS1 (FISH-negative) or NTRK (entrectinib)
- MoST 14: ALK (FISH-negative) (alectinib)

Relevant pan-cancer eligibility criteria include:

- Advanced and/or metastatic solid cancer of any histologic type, refractory or unsuitable for standard therapies for that cancer type, identified through the MoST molecular screening program (*note: this includes all subprograms within MoST, including Pan cancer and ASPIRATION*).
- For advanced and/or metastatic treatment-refractory solid cancer of any histologic type:
  - i. Participants must have received and failed all standard anticancer therapy or have documented unsuitability for any further standard therapy, if standard therapy exists.
  - ii. Clinical or radiological progression on or following last anticancer therapy unless such anticancer therapy stopped due to toxicity / treatment intolerance.

How to enrol:

### **A) For patients previously enrolled on ASPIRATION**

For a patient with the relevant treatment recommendation on an existing ASPIRATION MTB report:

1. If the patient is not at a participating centre, refer the patient to a centre with the relevant treatment substudy open (refer to the list on the TOGA website)
2. The participating substudy site will perform consent, screening and enrolment activities for the treatment substudy (the substudy consent form is the same as for ASPIRATION first line patients)

### **B) For patients NOT previously enrolled on ASPIRATION**

For a patient with a local gene alteration result (e.g. hotspot panel) but not previously enrolled in ASPIRATION or MoST pan-cancer:

1. Refer the patient to the Garvan for remote consent to the MoST pan-cancer screening program using the MoST referral form <https://infiniti.public.garvan.org.au/agcmp/most-referral> (NOT the ASPIRATION referral form)
2. Email the Garvan team at [most@garvan.org.au](mailto:most@garvan.org.au) requesting an expedited treatment recommendation based on SoC results
3. The Garvan will review the local result and determine if an expedited MTB report can be issued (turnaround approx. 1wk)
4. The Garvan will perform consent and screening activities for MoST pan-cancer
5. When the relevant treatment recommendation is received from the Garvan, refer the patient to a participating substudy site (if required), the substudy site will perform consent, screening and enrolment activities for the treatment substudy (the substudy consent form is the same as for ASPIRATION first line patients) (it is NOT necessary to wait for the full MoST genomic profiling result)

For any questions on MoST screening enrolment, please contact the Garvan at [most@garvan.org.au](mailto:most@garvan.org.au)

For any questions on MoST substudy enrolment, please contact the CTC at [most.study@sydney.edu.au](mailto:most.study@sydney.edu.au)